Prolor Biotech

Products

Development Focus

PROLOR Biotech is currently developing long-acting versions for the following existing therapeutic proteins and peptides:
  • MOD-4023: hGH-CTP – $3 billion current market
        
  • MOD-6030: GLP-1 / Glucagon dual receptor agonist – $2.0 billion current market
        
  • MOD-5017: Factor VIIa-CTP – $1.3 billion current market
        
  • MOD-9017: Factor IX-CTP – $0.7 billion current market